Statistiche di base
| CIK | 1468929 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Toppoint Holdings Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 15, 2026 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| May 15, 2026 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May [], 2026, by and between NEXGEL, INC., a Delaware corporation (the “Company”), and the persons and/or entities (each individually a “Buyer” and collectively the “Buyers”) named on the Schedule of Buyers attached to the Purchase Agreement (as defined below). Capitalized terms used herein and |
|
| May 15, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May [], 2026, by and between NEXGEL, INC., a Delaware corporation, with headquarters located at 2150 Cabot Blvd West, Suite B, Langhorne, PA 19047 (the “Company”), and the persons and/or entities (each individually a “Buyer” and collectively the “Buyers”) named on the Schedule of Buyers att |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 15, 2026 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, I |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| May 12, 2026 |
Exhibit 99.1 NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors Sequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa. – May 6, 2026 — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counte |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| April 30, 2026 |
Exhibit 99.1 NEXGEL Appoints Ian Blackman as Chief Financial Officer Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa. – April 27, 2026 — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-c |
|
| April 30, 2026 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”), effective as of April 27, 2026 (the “Effective Date”), is by and between NexGel, a Delaware corporation (the “Company”), and Ian Blackman, an individual (“Executive”). The Company and Executive shall sometimes be referred to herein individually as a “Party” and collectively as the “Parties”. BACKGRO |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| April 21, 2026 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| April 21, 2026 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| April 21, 2026 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April [], 2026, by and between NEXGEL, INC., a Delaware corporation, with headquarters located at 2150 Cabot Blvd West, Suite B, Langhorne, PA 19047 (the “Company”), and the persons and/or entities (each individually a “Buyer” and collectively the “Buyers”) named on the Schedule of Buyers a |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2026 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 21, 2026 |
AMENDMENT NO. 1 TO ASSET PURCHASE AND EXCLUSIVE LICENSE AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO ASSET PURCHASE AND EXCLUSIVE LICENSE AGREEMENT This Amendment No. 1 (“Amendment”) to that certain Asset Purchase and Exclusive License Agreement, dated as of March 6, 2026 (the “Agreement”), is entered into as of April 17, 2026 (the “Amendment Effective Date”), by and between Celularity Inc., a Delaware corporation (“Licensor”), and NexGel, Inc., a Delaware corporat |
|
| April 21, 2026 |
Exhibit 99.1 NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established regenerative |
|
| April 21, 2026 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April [], 2026, by and between NEXGEL, INC., a Delaware corporation (the “Company”), and the persons and/or entities (each individually a “Buyer” and collectively the “Buyers”) named on the Schedule of Buyers attached to the Purchase Agreement (as defined below). Capitalized terms used herein a |
|
| March 31, 2026 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary State of Organization CG Converting and Packaging, LLC (50% owned) Texas Sport Defense LLC (wholly owned) Delaware |
|
| March 31, 2026 |
NexGel, Inc. Insider Trading Policy Exhibit 19.1 NexGel, Inc. Insider Trading Policy In order to take an active role in the prevention of insider trading violations by its officers, directors, employees and other related individuals, the Board of Directors of NexGel, Inc. (the “Company”) has adopted the policies and procedures described in this Memorandum. Adoption of Insider Trading Policy. The Company has adopted the Insider Tradi |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, Inc. ( |
|
| March 10, 2026 |
ASSET PURCHASE AND EXCLUSIVE LICENSE AGREEMENT Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ASSET PURCHASE AND EXCLUSIVE LICENSE AGREEMENT This Asset Purchase and Exclusive License Agreement (this “Agreement”) is made effective as of March 6, 2026 (the “Effective Date”) by and between Celularity Inc., a |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| March 10, 2026 |
Exhibit 99.1 NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial pro |
|
| February 10, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264282 Prospectus Supplement (to Prospectus dated May 26, 2023) NEXGEL, INC. Up to $1,797,381 Series A Senior Secured Convertible Notes Shares of Common Stock Issuable Upon Conversion of the Series A Senior Secured Convertible NexGel, Inc. (the “Company.” “we,” or “our”) offering by this prospectus supplement up to $1,797,381 aggregate principa |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2026 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| January 30, 2026 |
Exhibit 17.1 January 29, 2026 NexGel, Inc. 2150 Cabot Boulevard West Suite B Langhorne, Pennsylvania 19067 RE: Resignation from NexGel, Inc. Dear Board of Directors: Effective as of February 2, 2026, I hereby resign as a member of the Board of Directors (the “Board”) of NexGel, Inc. (the “Company”), including as a member of any and all committees of the Board of Director on which I serve. I am lea |
|
| January 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| December 11, 2025 |
Exhibit 99.1 NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa. – December 11, 2025 — NEXGEL, Inc. (“NEXGEL” or the “Company”) |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGe |
|
| November 12, 2025 |
Exhibit 99.2 |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 12, 2025 |
NEXGEL Reports Third Quarter 2025 Financial Results Exhibit 99.1 NEXGEL Reports Third Quarter 2025 Financial Results LANGHORNE, Pa. – November 11, 2025 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results f |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 2, 2025 |
144 0001794090 XXXXXXXX LIVE 0001468929 NEXGEL, INC. 001-41173 2150 CABOT BLVD WEST, SUITE B LANGHORNE PA 19047 215 702-8550 Levy Adam R. Officer Director COMMON THE CHARLES SCHWAB CORPORATION 3000 Schwab Way Westlake TX 76262 16000 40000.00 8067580 10/02/2025 NASDAQ COMMON 10/15/2019 COMPENSATION ISSUER N 16000 10/15/2019 N/A N ADAM R LEVY C/O 2150 Cabot Blvd West, Suite B Langhorne PA 19047 COMM |
|
| September 25, 2025 |
144 0001961477 XXXXXXXX LIVE 0001468929 NEXGEL, INC. 001-41173 2150 CABOT BLVD WEST, SUITE B LANGHORNE PA 19047 215 702-8550 Henry Scott Robert Director COMMON THE CHARLES SCHWAB CORPORATION 3000 Schwab Way Westlake TX 76262 35515 108451.00 8067580 09/25/2025 NASDAQ COMMON 02/15/2024 COMPENSATION / DEAL ACQUIRED BETWEN: 2/15/24 TO 11/5/24 ISSUER N 35515 02/15/2024 NA Y FULL ACCOUNT TITLE: SCOTT RO |
|
| August 28, 2025 |
144 0001794090 XXXXXXXX LIVE 0001468929 NEXGEL, INC. 001-41173 2150 CABOT BLVD WEST, SUITE B LANGHORNE PA 19047 215 702-8550 Levy Adam R. Officer Common Charles Schwab Corp. 3000 Schwab Way Westake TX 76262 4000 9800.00 8067580 08/28/2025 Nasdaq Common 10/15/2019 Various: Founder Shares, PIPE, ESOP, Open Market Purchases Issuer N 4000 10/15/2019 Equity Compenation N Adam Levy 2150 Cabot Blvd West |
|
| August 12, 2025 |
NexGel, Inc. Investor Presentation, dated August 2025. Exhibit 99.2 |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, In |
|
| August 12, 2025 |
Exhibit 99.1 NEXGEL Reports Second Quarter 2025 Financial Results Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 5, 2025 |
Exhibit 99.1 NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors LANGHORNE, Pa. – August 5, 2025 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appoin |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 1, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 1, 2025 |
NEXGEL, INC. 413,044 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-264282 Prospectus Supplement (to Prospectus dated May 26, 2023) NEXGEL, INC. 413,044 Shares of Common Stock We are offering 413,044 shares of our common stock to investors pursuant to this prospectus supplement and the accompanying prospectus and a subscription agreement with each investor. In a concurrent private placement, or the Warrant Priv |
|
| August 1, 2025 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT Date: July 31, 2025 NexGel, Inc. 2150 Cabot Blvd West, Suite B Langhorne, Pennsylvania 19047 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with NexGel, Inc., a Delaware corporation (the “Company”), as follows: 1. This Subscription Agreement, including the Investor Information attached hereto as Annex A (collectively, this “ |
|
| August 1, 2025 |
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement LANGHORNE, Pa., August 1, 2025 — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive a |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 31, 2025 |
NexGel, Inc. Investor Presentation, dated July 2025. Exhibit 99.1 |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| July 14, 2025 |
NEXGEL and STADA AG Announce Expansion of Partnership for North America Exhibit 99.1 NEXGEL and STADA AG Announce Expansion of Partnership for North America LANGHORNE, Pa. – July 14, 2025 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consume |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| June 4, 2025 |
NexGel, Inc. Investor Presentation, dated June 2025. Exhibit 99.1 |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 13, 2025 |
Exhibit 99.1 NEXGEL Reports First Quarter 2025 Financial Results First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa. – May 13, 2025 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, I |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 27, 2025 |
NexGel, Inc.’s Insider Trading Policy Exhibit 19.1 NexGel, Inc. Insider Trading Policy In order to take an active role in the prevention of insider trading violations by its officers, directors, employees and other related individuals, the Board of Directors of NexGel, Inc. (the “Company”) has adopted the policies and procedures described in this Memorandum. Adoption of Insider Trading Policy. The Company has adopted the Insider Tradi |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, Inc. ( |
|
| March 27, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary State of Organization CG Converting and Packaging, LLC (50% owned) Texas NexGelRx, Inc. (wholly owned) Delaware Sport Defense LLC (wholly owned) Delaware |
|
| March 25, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| March 25, 2025 |
NexGel, Inc. Investor Presentation, dated March 2025. Exhibit 99.1 |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| March 24, 2025 |
Exhibit 99.1 NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2025 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| January 22, 2025 |
Exhibit 99.1 NEXGEL Issues Letter to Shareholders and Provides Guidance for 2024 and 2025 Management expects 2024 fourth quarter revenue of approximately $3.0 million and full year 2024 of approximately $8.6 million, representing growth year-over-year of over 100% for the third consecutive year Management expects to generate at least $13 million in revenue for 2025 and to achieve positive cash flo |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| January 6, 2025 |
Exhibit 10.1 2025 EXECUTIVE EMPLOYMENT AGREEMENT This 2025 Executive Employment Agreement (this “Agreement”), dated as of December 31, 2024, is by and between NEXGEL INC., a Delaware corporation (the “Company”), and Adam Levy, an individual (the “Executive”). The Company and the Executive shall sometimes be referred to herein individually as a “Party” and collectively as the “Parties”. BACKGROUND |
|
| January 6, 2025 |
Exhibit 10.2 2025 EXECUTIVE EMPLOYMENT AGREEMENT This 2025 Executive Employment Agreement (this “Agreement”), effective as of December 30, 2024, is by and between NEXGEL INC., a Delaware corporation (the “Company”), and Joseph F. McGuire, an individual (the “Executive”). The Company and the Executive shall sometimes be referred to herein individually as a “Party” and collectively as the “Parties”. |
|
| January 6, 2025 |
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer Exhibit 99.1 NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer LANGHORNE, Pa. – January 2, 2025 — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial |
|
| November 14, 2024 |
Exhibit 99.1 NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in Q2 of 2024 LANGHORNE, Pa. – November 13, 202 |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| November 13, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264282 Prospectus Supplement (to Prospectus dated May 26, 2023) NEXGEL, INC. 363,636 Units Consisting of 727,272 Shares of Common Stock Warrants to Purchase 363,636 Shares of Common Stock We are offering 363,636 units of NexGel, Inc., with each unit consisting of two shares of our common stock, par value $0.001 per share, and one warrant to pur |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGe |
|
| November 12, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 12, 2024 |
NEXGEL Announces $2,000,000 Registered Direct Offering Exhibit 99.1 NEXGEL Announces $2,000,000 Registered Direct Offering LANGHORNE, Pa., November 11, 2024 - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and |
|
| November 12, 2024 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT Date: November 11, 2024 NexGel, Inc. 2150 Cabot Blvd West, Suite B Langhorne, Pennsylvania 19047 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement, including the Investor Information attached hereto as Annex A (collectively, this “Agreement”), is made as of the date set forth |
|
| November 12, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 28, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| October 28, 2024 |
NexGel, Inc. Investor Presentation, dated October 2024. Exhibit 99.1 |
|
| October 10, 2024 |
Exhibit 99.1 NEXGEL Preannounces Expected Record Third Quarter 2024 Revenue of $2.85 Million, an Increase of Approximately 133% Year-Over-Year and 98% Sequentially LANGHORNE, Pa. – October 10, 2024 — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and con |
|
| October 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, In |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-CEN ☐ Form N-SAR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read |
|
| August 14, 2024 |
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million Exhibit 99.1 NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million LANGHORNE, Pa. – August 14, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| August 13, 2024 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT Date: August 8, 2024 NexGel, Inc. 2150 Cabot Blvd West, Suite B Langhorne, Pennsylvania 19047 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement, including the Investor Questionnaire attached hereto as Annex A (collectively, this “Agreement”), is made as of the date set forth b |
|
| August 13, 2024 |
NEXGEL Announces $1,110,000 Registered Direct Offering Led by Insiders Exhibit 99.1 NEXGEL Announces $1,110,000 Registered Direct Offering Led by Insiders LANGHORNE, Pa., August 12, 2024 — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for th |
|
| August 13, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 13, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264282 Prospectus Supplement (to Prospectus dated May 26, 2023) NEXGEL, INC. 222,000 Units Consisting 444,000 Shares of Common Stock Warrants to Purchase 222,000 Shares of Common Stock We are offering 222,000 units of NexGel, Inc. at a price to the public of $5.00 per unit, with each unit consisting of two shares of our common stock, par value |
|
| July 29, 2024 |
NexGel, Inc. Investor Presentation, dated July 2024. Exhibit 99.1 |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| July 8, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 8, 2024 |
Exhibit 99.1 NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively LANGHORNE, Pa., July 8, 2024 — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-conten |
|
| June 26, 2024 |
United States securities and exchange commission logo June 26, 2024 Adam Drapczuk Chief Financial Officer NEXGEL, INC. |
|
| June 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| June 13, 2024 |
QUICK LAW GROUP PC 1035 PEARL STREET SUITE 403 BOULDER, CO 80302 Phone: 720.259.3393 Facsimile: 303.845.7315 June 13, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Tracey Houser, Esq. Terence O’Brien, Esq. Re: NEXGEL, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 F |
|
| June 3, 2024 |
United States securities and exchange commission logo June 3, 2024 Adam Drapczuk Chief Financial Officer NEXGEL, INC. |
|
| May 20, 2024 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) entered into on as of May 15, 2024, by and between NexGel, Inc., a Delaware corporation (the “Buyer”), and Semmens Online Pty Ltd as Trustee for Semmens Business Trust, an Australian proprietary limited (the “Seller”). The Buyer and the Seller are referred to collectively herein as the “Parties” and individually |
|
| May 20, 2024 |
Exhibit 99.1 NEXGEL Acquires International Beauty Brand, Silly George Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa. – May 16, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healt |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, I |
|
| May 13, 2024 |
NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year Exhibit 99.1 NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year LANGHORNE, Pa. – May 13, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the first quarter ended March 31, 2024. Adam |
|
| May 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, Inc. ( |
|
| April 10, 2024 |
Exhibit 97 NEXGEL, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION A. OVERVIEW In accordance with the applicable rules of The Nasdaq Stock Market (the “Nasdaq Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), NEXGEL, INC. (the “Company”) has adopted this Policy (the “Policy”) to provide for the recovery of e |
|
| April 10, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary State of Organization CG Converting and Packaging, LLC (50% owned) Texas NexGelRx, Inc. (wholly owned) Delaware Sport Defense LLC (wholly owned) Delaware |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-CEN ☐ Form N-SAR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: |
|
| April 1, 2024 |
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year Exhibit 99.1 NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year LANGHORNE, Pa. – April 1, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year ended December |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 21, 2024 |
NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders Exhibit 99.1 NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders LANGHORNE, Pa. – February 21, 2024 - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for t |
|
| February 21, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 21, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 21, 2024 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT February 15, 2024 NexGel, Inc. 2150 Cabot Blvd West, Suite B Langhorne, Pennsylvania 19047 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement, including the Investor Questionnaire attached hereto as Annex A (collectively, this “Agreement”), is made as of the date set forth belo |
|
| February 21, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264282 Prospectus Supplement (to Prospectus dated May 26, 2023) NEXGEL, INC. 231,040 Units Consisting 462,090 Shares of Common Stock Warrants to Purchase 231,040 Shares of Common Stock We are offering 231,040 units of NexGel, Inc., with each unit consisting of two shares of our common stock, par value $0.001 per share, and one warrant to purcha |
|
| January 31, 2024 |
NexGel, Inc. Investor Presentation, dated January 2024. Exhibit 99.1 |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 16, 2024 |
Resignation letter of Miranda J. Toledano dated January 9, 2024 Exhibit 17.1 January 9, 2024 NexGel, Inc. 2150 Cabot Boulevard West Suite B Langhorne, Pennsylvania 19067 RE: Resignation from NexGel, Inc. Dear Board of Directors: Effective as of March 31, 2024, I hereby resign as a member of the Board of Directors (the “Board”) of NexGel, Inc. (the “Company”), including as a member of any and all committees of the Board of Director on which I serve. My resignat |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| December 29, 2023 |
Exhibit 10.1 2024 EXECUTIVE EMPLOYMENT AGREEMENT This 2024 Executive Employment Agreement (this “Agreement”), effective as of December 26, 2023, is by and between NEXGEL INC., a Delaware corporation (the “Company”), and Adam Levy, an individual (the “Executive”). The Company and the Executive shall sometimes be referred to herein individually as a “Party” and collectively as the “Parties”. BACKGRO |
|
| December 12, 2023 |
Resignation letter of David Stefansky dated December 7, 2023 Exhibit 17.1 December 7, 2023 NexGel, Inc. 2150 Cabot Boulevard West Suite B Langhorne, Pennsylvania 19067 RE: Resignation from NexGel, Inc. Dear Board of Directors: Effective as of December 31, 2023, I hereby resign as a member of the Board of Directors (the “Board”) of NexGel, Inc. (the “Company”), including as a member of any and all committees of the Board of Director on which I serve. I am le |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| December 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| December 11, 2023 |
Exhibit 99.1 NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America LANGHORNE, Pa. – December 11, 2023 - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announce |
|
| December 5, 2023 |
Exhibit 99.1 NEXGEL Acquires Kenkoderm Psoriasis Skincare Line Acquisition expands NEXGEL’s health and wellness consumer product portfolio Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins Kenkoderm for the trailing twelve months is profitable and expected to be immediately accretive to NEXGEL LANGHORNE, Pa. – December 5, 2023 – NEXGEL, Inc |
|
| December 5, 2023 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) entered into on as of November 30, 2023, by and between NexGel, Inc., a Delaware corporation (the “Buyer”), and Olympus Trading Company, LLC, a Virginia limited liability company (the “Seller”). The Buyer and the Seller are referred to collectively herein as the “Parties” and individually as |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGe |
|
| November 13, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| November 13, 2023 |
Exhibit 99.1 NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa. – November 13, 2023 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer appli |
|
| October 30, 2023 |
NEXGEL Secures Supply Agreement with AbbVie Exhibit 99.1 NEXGEL Secures Supply Agreement with AbbVie LANGHORNE, Pa. – October 30, 2023 NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that its subsidiary, CG Converting and Packaging, has executed a supply agreement with AbbVie Inc. (NYSE: ABBV), a glob |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer o |
|
| August 14, 2023 |
Exhibit 99.1 NEXGEL Reports Second Quarter 2023 Record Revenue of $1.17 Million, an Increase of 108% Year-Over-Year LANGHORNE, Pa. – August 14, 2023 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced financial results for the second quarter ended June 30, 202 |
|
| August 14, 2023 |
NexGel, Inc. Investor Presentation, dated August 2023. Exhibit 99.2 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, In |
|
| June 9, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| June 7, 2023 |
June 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| June 7, 2023 |
NexGel, Inc. 2150 Cabot Blvd West, Suite B Langhorne, PA 19047 NexGel, Inc. 2150 Cabot Blvd West, Suite B Langhorne, PA 19047 June 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Esq. RE: NexGel, Inc. Registration Statement on Form S-3 Originally Filed April 13, 2022, as amended Request for Acceleration File No. 333-264282 Ladies and Gentleme |
|
| June 6, 2023 |
NexGel, Inc. Investor Presentation, dated June, 2023. Exhibit 99.1 |
|
| June 6, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 26, 2023 |
As filed with the Securities and Exchange Commission on May 26, 2023 As filed with the Securities and Exchange Commission on May 26, 2023 Registration No. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, I |
|
| May 15, 2023 |
Exhibit 99.1 NEXGEL Reports First Quarter 2023 Financial Results 2023 first quarter revenue increased 56.6% year-over-year to $620 thousand Approximately $5.8 million in cash and securities at March 31, 2023 Provides second quarter 2023 revenue guidance of $1.0 million, an increase of 78.2% year-over-year LANGHORNE, Pa. – May 15, 2023 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 28, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary State of Organization NexGelRx, Inc. (wholly owned) Delaware Sport Defense LLC (wholly owned) Delaware |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGel, Inc. ( |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| March 27, 2023 |
Exhibit 99.1 NEXGEL Reports Fourth Quarter and Full Year 2022 Financial Results 2022 revenue increased 32% YoY to $2.05 million, while gross profit margin improved As of December 31, 2022, had over $6.6 million in cash and securities which is sufficient to operate through 2025 LANGHORNE, Pa. – March 27, 2023 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-g |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 2, 2023 |
Exhibit 99.1 NEXGEL Acquires 50% Interest in Newly Formed Joint Venture with C.G. Laboratories for Converting and Packaging Business Strategic investment in CG Labs’ revenue generating and already profitable business increases NEXGEL’s capacity, improves margins and streamlines supply chain LANGHORNE, Pa. – March 2, 2023 – NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading |
|
| March 2, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| January 17, 2023 |
NEXGEL Appoints Scott Henry, CFA to Board of Directors and Audit Committee Exhibit 99.1 NEXGEL Appoints Scott Henry, CFA to Board of Directors and Audit Committee LANGHORNE, Pa. – January 17, 2023 – NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2023 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| January 17, 2023 |
Resignation letter of Yaakov Spinrad dated January 16, 2023 Exhibit 17.1 January 16, 2023 NexGel, Inc. 2150 Cabot Boulevard West Suite B Langhorne, Pennsylvania 19067 RE: Resignation from NexGel, Inc. Dear Board of Directors: Effective as of the date of this letter, I hereby resign as a member of the Board of Directors of NexGel, Inc. (the “Company”), including as a member of any and all committees of the Board of Director on which I serve. My resignation |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| January 6, 2023 |
Exhibit 10.1 2023 EXECUTIVE EMPLOYMENT AGREEMENT This 2023 Executive Employment Agreement (this ?Agreement?), effective as of December 30, 2022, is by and between NEXGEL INC., a Delaware corporation (the ?Company?), and Adam Levy, an individual (the ?Executive?). The Company and the Executive shall sometimes be referred to herein individually as a ?Party? and collectively as the ?Parties?. BACKGRO |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| December 7, 2022 |
NEXGEL Announces Share Repurchase Program Exhibit 99.1 NEXGEL Announces Share Repurchase Program LANGHORNE, Pa. – December 7, 2022 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that its Board of Directors has approved a share repurchase program, effective immediately, with authorization to |
|
| November 8, 2022 |
Exhibit 99.1 NEXGEL Reports Third Quarter 2022 Financial Results Revenue increased 69.6% YoY while gross profit margin improved both sequentially and YoY to 26% LANGHORNE, Pa. – November 8, 2022 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41173 NexGe |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-41173 26-4042544 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| September 9, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| September 6, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer o |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36278 NexGel, In |
|
| August 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 10, 2022 |
Exhibit 99.1 NEXGEL Reports Second Quarter 2022 Financial Results Second quarter 2022 revenue increased 35% YoY and 42% sequentially to $561 Thousand Company sees growth in its branded consumer products and launches MEDAGEL Pro Pads LANGHORNE, Pa. ? August 10, 2022 ? NEXGEL, Inc. (?NEXGEL? or the ?Company?) (NASDAQ: ?NXGL?), a leading provider of ultra-gentle, high-water-content hydrogel products |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 18, 2022 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| July 8, 2022 |
PRE 14A 1 formpre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D. |
|
| May 12, 2022 |
Exhibit 99.1 NEXGEL Reports First Quarter 2022 Financial Results First quarter 2022 revenue increased 48% YoY to $396 Thousand Company launched two new consumer OTC products using its HYDROGEL Technology: The MEDAGEL ClearComfort Hydrogel Patch and The MEDAGEL Bug Bite Relief Patch LANGHORNE, Pa. ? May 12, 2022 ? NEXGEL, Inc. (?NEXGEL? or the ?Company?) (NASDAQ: ?NXGL?), a leading provider of ultr |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer of i |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| April 18, 2022 |
United States securities and exchange commission logo April 18, 2022 Adam Levy Chief Executive Officer NexGel, Inc. |
|
| April 13, 2022 |
Calculation of Filing Fee Tables EX-FILING FEES 7 tm2212046d1ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-3 (Form Type) NEXGEL, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price P |
|
| April 13, 2022 |
Equity Distribution Agreement dated April 13, 2022 by and between NexGel, Inc., and Maxim Group LLC Exhibit 10.1 NexGel, Inc. Up to $2,700,000 Shares of Common Stock Equity Distribution Agreement April 13, 2022 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: NexGel, Inc., a Delaware corporation (the "Company"), proposes to issue and sell through Maxim Group LLC (the "Agent"), as exclusive sales agent, shares of common stock, par value $0.001 per share ( |
|
| April 13, 2022 |
Form of indenture for subordinated debt securities Exhibit 4.5 NEXGEL, INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS ARTICLE I DEFINITIONS 3 Section 1.1 Definitions of Terms 3 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities 5 Section 2.2 Form of Securities and Trustee?s Certificate 7 Section 2.3 |
|
| April 13, 2022 |
As filed with the Securities and Exchange Commission on April 13, 2022 As filed with the Securities and Exchange Commission on April 13, 2022 Registration No. |
|
| April 13, 2022 |
Form of indenture for senior debt securities Exhibit 4.4 - NEXGEL, INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS ARTICLE I DEFINITIONS 3 Section 1.1 Definitions of Terms 3 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities 5 Section 2.2 Form of Securities and Trustee?s Certificate 6 Section 2.3 Deno |
|
| March 21, 2022 |
Exhibit 99.1 NEXGEL Reports Fourth Quarter and Full Year 2021 Financial Results Full year 2021 revenue increased 130% YoY to $1.55 million As of December 31, 2021, the Company had $13.35 million in cash LANGHORNE, Pa. ? March 21, 2022 ? NEXGEL, Inc. (?NEXGEL? or the ?Company?) (NASDAQ: ?NXGL?), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer app |
|
| March 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36 |
|
| March 21, 2022 |
Exhibit 21.1 ? Subsidiaries of the Registrant ? Name of Subsidiary ? State of Organization NexGelRx, Inc. (wholly owned) ? Delaware Sport Defense LLC (wholly owned) ? Delaware ? |
|
| March 17, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| January 12, 2022 |
EX-99.1 2 tm222659d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEXGEL Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch - ClearComfort Patches Prevent and Treat Blisters Using Advanced Hydrogel Technology - LANGHORNE, Pa. – January 12, 2022 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare a |
|
| January 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| January 10, 2022 |
Exhibit 99.1 NEXGEL Provides 2021 Year in Review Significant progress developing and identifying innovative hydrogel applications across consumer and medical uses culminating in December 2021 IPO As of December 31, 2021, NEXGEL had approximately $13.3 Million cash to advance its programs as part of its growth strategy LANGHORNE, PA. ? January 10, 2022 ? NEXGEL, Inc. (?NEXGEL? or the ?Company?) (NA |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 001-41173 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| December 27, 2021 |
NexGel, Inc. Announces Closing of $14.2 Million Initial Public Offering EX-99.2 6 tm2136341d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 NexGel, Inc. Announces Closing of $14.2 Million Initial Public Offering LANGHORNE, PA, December 27, 2021 — NexGel, Inc. (“NexGel” or the “Company”) (Nasdaq: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery a |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-56066 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| December 27, 2021 |
Exhibit 4.1 REPRESENTATIVE?S PURCHASE WARRANT NEXGEL, INC. Warrant Shares: 155,100 Initial Exercise Date: June 21, 2022 This REPRESENTATIVE?S PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Maxim Partners LLC or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| December 27, 2021 |
NexGel, Inc. Announces Listing on Nasdaq and Pricing of $14.2 Million Initial Public Offering Exhibit 99.1 NexGel, Inc. Announces Listing on Nasdaq and Pricing of $14.2 Million Initial Public Offering LANGHORNE, PA, December 21, 2021 ? NexGel, Inc. (?NexGel? or the ?Company?) (Nasdaq:NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today anno |
|
| December 27, 2021 |
424B4 1 tm2128342d15424b4.htm 424B4 Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-260897 and 333-261821 2,585,000 Units Consisting of 2,585,000 Shares of Common Stock and Warrants to Purchase 2,585,000 Shares of Common Stock NexGel, Inc. We are offering 2,585,000 units of NexGel, Inc., with each unit consisting of one share of our common stock, par value $0.001 per share, and one warrant |
|
| December 27, 2021 |
Exhibit 10.1 NEXGEL, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of December 27, 2021 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of December 27, 2021 (?Agreement?), between NexGel, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and Continental Stock Transfer & Trust Company, a New Y |
|
| December 27, 2021 |
EX-1.1 2 tm2136341d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 2,585,000 SHARES of Common Stock AND 2,585,000 WARRANTS TO PURCHASE 2,585,000 SHARES of Common Stock OF NEXGEL, INC. UNDERWRITING AGREEMENT December 21, 2021 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: The undersigned, |
|
| December 21, 2021 |
As filed with the Securities and Exchange Commission on December 21, 2021 S-1MEF 1 tm2128342d14s1mef.htm S-1MEF As filed with the Securities and Exchange Commission on December 21, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 form s-1 registration statement UNDER THE SECURITIES ACT OF 1933 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 3841 26-4042544 (State or other jurisdiction of inco |
|
| December 17, 2021 |
December 17, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NexGel, Inc. Registration Statement on Form S-1, as amended Filed November 9, 2021 File No. 333-260897 Ladies and Gentlemen: As the underwriter of the proposed offering of NexGel, Inc. (the “Company”), we hereby join the Company’s request for acceleratio |
|
| December 17, 2021 |
CORRESP 1 filename1.htm December 17, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor RE: NexGel, Inc. Registration Statement on Form S-1 Originally Filed November 9, 2021, as amended Request for Acceleration File No. 333-260897 Ladies and Gentlemen: Pursuant to Rule 461 of the Rules an |
|
| December 16, 2021 | ||
| December 16, 2021 |
December 16, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| December 15, 2021 |
8-A12B 1 tm2128342d98a12b.htm 8-A12B United States Securities and Exchange Commission Washington, D.C. 20549 FORM 8-A For registration of certain classes of securities pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4042544 (State or other jurisdiction of incorporation or organization) (I.R.S. E |
|
| December 14, 2021 |
CORRESP 1 filename1.htm December 14, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NexGel, Inc. Registration Statement on Form S-1, as amended Filed November 9, 2021 File No. 333-260897 Ladies and Gentlemen: As the underwriter of the proposed offering of NexGel, Inc. (the “Company”), we hereby join the Company’s |
|
| December 14, 2021 |
CORRESP 1 filename1.htm December 14, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor RE: NexGel, Inc. Registration Statement on Form S-1 Originally Filed November 9, 2021, as amended Request for Acceleration File No. 333-260897 Ladies and Gentlemen: Pursuant to Rule 461 of the Rules an |
|
| December 10, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 SHARES of Common Stock AND WARRANTS TO PURCHASE SHARES of Common Stock OF NEXGEL, INC. UNDERWRITING AGREEMENT , 2021 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: The undersigned, NexGel, Inc., a company incorporated under the laws of Delaware (collectively with |
|
| December 10, 2021 |
Form of Warrant Agent Agreement (including form of Common Warrant). Exhibit 4.6 NEXGEL, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of , 2021 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2021 (?Agreement?), between NexGel, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose tru |
|
| December 10, 2021 |
S-1/A 1 tm2128342d6s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on December 10, 2021 Registration No. 333-260897 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO form s-1 registration statement UNDER THE SECURITIES ACT OF 1933 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 3841 26-4042544 (State or o |
|
| December 10, 2021 |
Form of Underwriter’s Warrant. EX-4.7 4 tm2128342d6ex4-7.htm EXHIBIT 4.7 Exhibit 4.7 REPRESENTATIVE’S PURCHASE WARRANT NEXGEL, INC. Warrant Shares: 1 Initial Exercise Date: , 20222 This REPRESENTATIVE’S PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| December 10, 2021 |
Exhibit 10.23 THIRD AMENDMENT TO THE SENIOR SECURED PROMISSORY NOTE, WARRANTS, AND SECURITIES PURCHASE AGREEMENT DATED MARCH 11, 2021 THIS THIRD AMENDMENT to the Note (as defined below), Warrants (as defined below), and SPA (as defined below) (the ?Amendment?) is entered into on December 10, 2021 (the ?Effective Date?), by and between Nexgel, Inc., a Delaware corporation (the ?Company?), and Auctu |
|
| December 6, 2021 |
As filed with the Securities and Exchange Commission on December 6, 2021 S-1/A 1 tm2128342d5s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on December 6, 2021 Registration No. 333-260897 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO form s-1 registration statement UNDER THE SECURITIES ACT OF 1933 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 3841 26-4042544 (State or ot |
|
| December 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-56066 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| December 2, 2021 |
As filed with the Securities and Exchange Commission on December 2, 2021 S-1/A 1 tm2128342d4s-1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on December 2, 2021 Registration No. 333-260897 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO form s-1 registration statement UNDER THE SECURITIES ACT OF 1933 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 3841 26-4042544 (State or o |
|
| December 2, 2021 |
Exhibit 3.6 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NEXGEL, INC. NEXGEL, Inc. (the ?Corporation?), a corporation duly organized and existing under the laws of the State of Delaware, by its duly authorized officer, does hereby certify that: 1. The Board of Directors of the Corporation has duly adopted resolutions (i) authorizing the Corporation to execute a |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-56066 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| November 9, 2021 |
Exhibit 10.22 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?), entered into and effective as of November 4, 2021, is by and between NEXGEL INC., a Delaware corporation (the ?Company?), and Adam Levy, an individual (the ?Executive?). The Company and the Executive shall sometimes be referred to herein as the ?Parties?. BACKGROUND A. The Executive currently serves |
|
| November 9, 2021 |
S-1 1 tm2128342d3s-1.htm FORM S-1 As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 form s-1 registration statement UNDER THE SECURITIES ACT OF 1933 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 3841 26-4042544 (State or other jurisdiction of incorpora |
|
| November 3, 2021 |
Exhibit 10.1 SECOND AMENDMENT TO THE SENIOR SECURED PROMISSORY NOTE, WARRANTS, AND SECURITIES PURCHASE AGREEMENT DATED MARCH 11, 2021 THIS SECOND AMENDMENT to the Note (as defined below), Warrants (as defined below), and SPA (as defined below) (the “Amendment”) is entered into on October 28, 2021 (the “Effective Date”), by and between Nexgel, Inc., a Delaware corporation (the “Company”), and Auctu |
|
| November 3, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-56066 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| October 1, 2021 |
United States securities and exchange commission logo October 1, 2021 Adam Levy President and Chief Executive Officer NexGel, Inc. |
|
| September 24, 2021 |
DRSLTR 1 filename1.htm ▀ ▀ ▀ QUICK LAW GROUP PC 1035 PEARL STREET SUITE 403 BOULDER, CO 80302 Phone: 720.259.3393 Facsimile: 303.845.7315 September 24, 2021 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: NEXGEL, Inc. Draft Registration Statement on Form S-1 Ladies and Gentlemen: On behalf of NE |
|
| September 24, 2021 |
DRS 1 filename1.htm As confidentially submitted to the U.S. Securities and Exchange Commission on September 24, 2021 pursuant to the Jumpstart Our Business Startups Act of 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 form s-1 registration statement UNDER THE SECURITIES ACT OF 1933 NexGel, Inc. (Exact name of registrant as specified in its chart |
|
| September 15, 2021 |
Exhibit 99.1 NEXGEL Announces Appointment of Miranda Toledano to Board of Directors Ms. Toledano Brings Over Two Decades of Biopharmaceutical Wall Street Experience to NEXGEL LANGHORNE, Pa. ? September 9, 2021 ? NEXGEL, Inc. (?NEXGEL? or the ?Company?), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that the Compan |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-56066 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| September 8, 2021 |
Exhibit 10.3 SUBORDINATION AGREEMENT THIS SUBORDINATION AGREEMENT (this ?Agreement?), is entered into as of September 2, 2021 (the ?Effective Date?), by and between NEXGEL, INC., a Delaware corporation (the ?Borrower?), the persons and/or entities (each individually a ?Subordinated Secured Party? and collectively the ?Subordinated Secured Parties?) named on the Schedule of Buyers attached to the P |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-56066 26-4042544 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| September 8, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 2, 2021, by and between NEXGEL, INC., a Delaware corporation, with headquarters located at 2150 Cabot Blvd West, Suite B, Langhorne, PA 19047 (the ?Company?), and the persons and/or entities (each individually a ?Buyer? and collectively the ?Buyers?) named on the Schedule of Buyer |
|
| September 8, 2021 |
EX-4.1 2 tm2127156d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) |
|
| September 8, 2021 |
EX-10.4 7 tm2127156d1ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of September 2, 2021, by and between NEXGEL, INC., a Delaware corporation (the "Company"), and the persons and/or entities (each individually a “Buyer” and collectively the “Buyers”) named on the Schedule of Buyers attached to the Purchase Agreement (as |
|
| September 8, 2021 |
Exhibit 10.5 Common Stock Lock-Up Agreement Date: September 2, 2021 Maxim Group LLC 405 Lexington Avenue New York, NY 10174 Ladies and Gentlemen: As an inducement to Maxim Group LLC (the ?Underwriter?), to execute an underwriting agreement (the ?Underwriting Agreement?), in its capacity as Underwriter, providing for a public offering (the ?Offering?) of common stock, par value $0.001 per share (th |
|
| September 8, 2021 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| September 8, 2021 |
Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”), is entered into as of September 2, 2021 (the “Effective Date”), by and between NEXGEL, INC., a Delaware corporation (the “Borrower”), and the persons and/or entities (each individually a “Secured Party” and collectively the “Secured Parties”) named on the Schedule of Buyers attached to the Purchase Agreement (as defined be |
|
| August 16, 2021 |
? Exhibit 10.1 ? FIRST AMENDMENT TO THE SENIOR SECURED PROMISSORY NOTE, WARRANTS, AND SECURITIES PURCHASE AGREEMENT DATED MARCH 11, 2021 ? THIS FIRST AMENDMENT to the Note (as defined below), Warrants (as defined below), and SPA (as defined below) (the ?Amendment?) is entered into on August 13, 2021 (the ?Effective Date?), by and between Nexgel, Inc., a Delaware corporation (the ?Company?), and Au |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D. |
|
| August 5, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NEXGEL, INC. NEXGEL, Inc. (the “Corporation”), a corporation duly organized and existing under the laws of the State of Delaware, by its duly authorized officer, does hereby certify that: 1. The Board of Directors of the Corporation has duly adopted resolutions (i) authorizing the Corporation to exe |
|
| August 5, 2021 |
8-K 1 tm2124153d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 NEXGEL, INC. (Exact name of registrant as specified in its charter) Delaware 000-56066 26-4042544 (State or other jurisdiction (Commiss |
